Events

Online info day: European Innovation Ecosystems and “Startup Europe” calls for proposals (EIC)
SEP
Tue
21
09:30 - 16:30

This was 3 years ago

Location

Webinar

Programmes
EIC EIE

The European Innovation Council (EIC) and SMEs Executive Agency (EISMEA) will highlight the 2021-2022 workprogrammes of European Innovation Ecosystsems (EIE) and the Startup Europe Iitiative under the EIC workprogramme 2021.

Applications for calls are open and deadline for submission:

  • first EIE calls: 26 October 2021 and 10 November 2021
  • first Startup calls: 18 Novermber 2021 

More detailed information and link to register to the webinar: here

Deadline for registration to this webinar is 17 September - 23:00

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.